Consolidated Portfolio Review Corp Acquires Shares of 276,530 Roivant Sciences Ltd. $ROIV

Key Points

• Consolidated Portfolio Review Corp acquired 276,530 shares of Roivant Sciences (NASDAQ:ROIV) in Q4, valued at about $6.0 million, making ROIV roughly 0.5% of its portfolio and its 21st largest holding.
• Insiders have been heavy sellers recently — directors sold notable blocks (including 425,000 shares by Daniel Allen Gold) and insiders disposed of 4,595,624 shares worth $124.85 million in the past three months, while insiders still own 10.8% of the stock.
• ROIV has a market capitalization of about $21.0 billion, a 52-week range of $9.90–$30.33, and an average analyst consensus of “Moderate Buy” with an average price target of $29.50 (9 Buy, 1 Hold, 1 Sell).

Consolidated Portfolio Review Corp acquired a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 276,530 shares of the company's stock, valued at approximately $6,001,000. Roivant Sciences comprises about 0.5% of Consolidated Portfolio Review Corp's portfolio, making the stock its 21st largest position.

Other hedge funds also recently bought and sold shares of the company. Jones Financial Companies Lllp raised its holdings in Roivant Sciences by 226.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company's stock valued at $25,000 after acquiring an additional 1,148 shares during the last quarter. Allworth Financial LP grew its stake in shares of Roivant Sciences by 48.1% in the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company's stock valued at $27,000 after buying an additional 583 shares during the period. Bessemer Group Inc. grew its stake in shares of Roivant Sciences by 41.5% in the 3rd quarter. Bessemer Group Inc. now owns 1,852 shares of the company's stock valued at $28,000 after buying an additional 543 shares during the period. Farther Finance Advisors LLC grew its stake in shares of Roivant Sciences by 59.6% in the 4th quarter. Farther Finance Advisors LLC now owns 3,600 shares of the company's stock valued at $78,000 after buying an additional 1,345 shares during the period. Finally, Aster Capital Management DIFC Ltd grew its stake in shares of Roivant Sciences by 75.8% in the 3rd quarter. Aster Capital Management DIFC Ltd now owns 4,405 shares of the company's stock valued at $67,000 after buying an additional 1,900 shares during the period. Institutional investors and hedge funds own 64.76% of the company's stock.

Roivant Sciences Stock Performance

NASDAQ:ROIV opened at $29.39 on Thursday. The stock has a market capitalization of $21.03 billion, a P/E ratio of -25.12 and a beta of 1.20. The company has a 50 day moving average price of $27.83 and a 200 day moving average price of $22.99. Roivant Sciences Ltd. has a fifty-two week low of $9.90 and a fifty-two week high of $30.33.

Analysts Set New Price Targets

ROIV has been the subject of several analyst reports. Guggenheim increased their price target on shares of Roivant Sciences from $28.00 to $30.00 and gave the company a "buy" rating in a research note on Monday, February 9th. TD Cowen reissued a "buy" rating on shares of Roivant Sciences in a research note on Wednesday, March 4th. Weiss Ratings cut shares of Roivant Sciences from a "hold (c-)" rating to a "sell (d)" rating in a research note on Monday, February 9th. HC Wainwright increased their price target on shares of Roivant Sciences from $33.00 to $34.00 and gave the company a "buy" rating in a research note on Wednesday, March 4th. Finally, Sanford C. Bernstein initiated coverage on shares of Roivant Sciences in a research note on Friday, March 20th. They issued an "outperform" rating and a $35.00 price target for the company. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $29.50.

Insider Activity

In related news, Director Daniel Allen Gold sold 425,000 shares of the stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $26.67, for a total transaction of $11,334,750.00. Following the completion of the transaction, the director owned 15,928,113 shares of the company's stock, valued at approximately $424,802,773.71. This trade represents a 2.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Melissa B. Epperly sold 41,861 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $28.68, for a total transaction of $1,200,573.48. Following the transaction, the director directly owned 15,804 shares of the company's stock, valued at $453,258.72. The trade was a 72.59% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 4,595,624 shares of company stock worth $124,848,136 in the last three months. 10.80% of the stock is currently owned by corporate insiders.

Roivant Sciences Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.

Want to see what other hedge funds are holding ROIV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.